Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease.

Silva A, Naia L, Dominguez A, Ribeiro M, Rodrigues J, Vieira OV, Lessmann V, Rego AC.

Neurodegener Dis. 2015;15(4):207-18. doi: 10.1159/000375447. Erratum in: Neurodegener Dis. 2015;15(4):258.

Refractory restless legs syndrome remitting after dual kidney transplantation.

Albanese M, Placidi F, Romigi A, Liguori C, Marchi A, Mercuri NB, Marciani MG, Izzi F.

Parkinsonism Relat Disord. 2015 Jan;21(1):81-3. doi: 10.1016/j.parkreldis.2014.10.023. No abstract available.

Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.

Seraji-Bozorgzad N, Bao F, George E, Krstevska S, Gorden V, Chorostecki J, Santiago C, Zak I, Caon C, Khan O.

Mov Disord. 2015 Sep;30(10):1400-4. doi: 10.1002/mds.26323.

Is de Zurbarán's Saint Hugo in the refectory" the earliest example of portrayal of Parkinson's disease?"

Lazzeri D, Castello MF, Zhang YX, Persichetti P.

Rev Neurol (Paris). 2015 May;171(5):452-4. doi: 10.1016/j.neurol.2015.02.006. No abstract available.

Deep brain stimulation versus electroconvulsive therapy in Parkinson's disease.

Kellner CH, Kellner DA.

J ECT. 2015 Jun;31(2):e23. doi: 10.1097/YCT.0000000000000213. No abstract available.

Exploring factors related to physical activity in cervical dystonia.

Zetterberg L, Urell C, Anens E.

BMC Neurol. 2015 Dec 1;15:247. doi: 10.1186/s12883-015-0499-6.

Abnormal functional connectivity density in Parkinson's disease.

Zhang J, Bi W, Zhang Y, Zhu M, Zhang Y, Feng H, Wang J, Zhang Y, Jiang T.

Behav Brain Res. 2015 Mar 1;280:113-8. doi: 10.1016/j.bbr.2014.12.007.

Sensory Attenuation Assessed by Sensory Evoked Potentials in Functional Movement Disorders.

Macerollo A, Chen JC, Pareés I, Kassavetis P, Kilner JM, Edwards MJ.

PLoS One. 2015 Jun 19;10(6):e0129507. doi: 10.1371/journal.pone.0129507.

Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study.

Gabery S, Georgiou-Karistianis N, Lundh SH, Cheong RY, Churchyard A, Chua P, Stout JC, Egan GF, Kirik D, Petersén Å.

PLoS One. 2015 Feb 6;10(2):e0117593. doi: 10.1371/journal.pone.0117593.

The Molecular Genetics of Restless Legs Syndrome.

Rye DB.

Sleep Med Clin. 2015 Sep;10(3):227-33, xii. doi: 10.1016/j.jsmc.2015.05.015. Review.

Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.

Deusser J, Schmidt S, Ettle B, Plötz S, Huber S, Müller CP, Masliah E, Winkler J, Kohl Z.

J Neurochem. 2015 Nov;135(3):589-97. doi: 10.1111/jnc.13253.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Galduróz JC, Ramos AC, Santos-Galduróz RF.

Neurology. 2015 Mar 31;84(13):1386-7. doi: 10.1212/WNL.0000000000001458. No abstract available.

Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.

Ren R, Sun Y, Zhao X, Pu X.

Clin Chem Lab Med. 2015 Sep 1;53(10):1495-506. doi: 10.1515/cclm-2014-0783. Review.

Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia.

Meoni S, Zurowski M, Lozano AM, Hodaie M, Poon YY, Fallis M, Voon V, Moro E.

Neurology. 2015 Aug 4;85(5):433-40. doi: 10.1212/WNL.0000000000001811.

Two novel mutations of the SETX gene and ataxia with oculomotor apraxia type 2.

Pera J, Lechner S, Biskup S, Strach M, Grodzicki T, Slowik A.

Clin Neurol Neurosurg. 2015 Jan;128:44-6. doi: 10.1016/j.clineuro.2014.10.024. No abstract available.